Disentangling the lifespans of hepatitis C virus‐infected cells and intracellular vRNA replication‐complexes during direct‐acting anti‐viral therapy. Issue 3 (22nd November 2019)

• Record Type: Journal Article
• Authors: Cardozo, Erwing Fabian; Ji, Dong; Lau, George; Schinazi, Raymond F.; Chen, Guo‐feng; Ribeiro, Ruy M.; Perelson, Alan S.
• Is Part Of: Journal of viral hepatitis. Volume 27:Issue 3(2020)
• Page Start: 261
• Page End: 269
• Publication Date: 2019-11-22
• Subjects: ALT kinetics -- hepatitis C -- mathematical modelling -- SODAPI study -- sofosbuvir -- viral dynamics; Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.13229
• Languages: English
• ISSNs: 1352-0504

Abstract

Abstract: The decay rate of hepatitis C virus (HCV)‐infected cells during therapy has been used to determine the duration of treatment needed to attain a sustained virologic response, but with direct‐acting anti‐virals (DAA), this rate has been difficult to estimate. Here, we show that it is possible to estimate it, by simultaneously analysing the viral load and alanine aminotransferase (ALT) kinetics during combination DAA therapy. We modelled the HCV RNA and ALT serum kinetics in 26 patients with chronic HCV genotype 1b infection, under four different sofosbuvir‐based combination treatments. In all patients, ALT decayed exponentially to a set point in the normal range by 1‐3 weeks after initiation of therapy. The model indicates that the ALT decay rate during the first few weeks after initiation of therapy reflects the death rate of infected cells, with an estimated median half‐life of 2.5 days in this patient population. This information allows independent estimation of the rate of loss of intracellular replication complexes during therapy. Our model also predicts that the final ALT set point is not related to the release of ALT by dying HCV‐infected cells. Using ALT data, one can separately obtain information about the rate of 'cure' of HCV‐infected cells versus their rate of death, something not possible when analysing only HCV RNA data. This information can be used to compare the effects of different DAA combinations and to rationally evaluate their anti‐viral effects.